Dominic Schwarz | Scientist
Roche Glycart AG
Dominic Schwarz is a scientists at the Roche Innovation Center Zürich, where he specialized in next-generation cytokine armoring of cellular therapies. He completed his university education in biochemistry and synthetic biology at the Technical University Munich and performed his doctoral education under a Marie Sklodowska-Curie grant through the Roche Innovation Center Zürich and Ludwig-Maximilians University Munich. His doctoral work focused on the engineering of orthogonal cytokine receptors for adoptive cell therapies.
Appearances:
Festival of Biologics Day 1 @ 14:30
Novel Orthogonal Receptor Platform Activating the IL12 Pathway in CAR-T Cells Using a Small-Molecule Ligand
We present an orthogonal split-antibody-based Interleukin-12 receptor that exhibits high affinity for the inert small molecule chelator DOTAM. DOTAM-inducible Interleukin-12 receptors (D12Rs) result in attenuated agonism which is potentiated during concurrent CAR signaling. CAR D12R T cells showed enhanced cytotoxicity under repeated antigen exposure and mediated durable in vivo efficacy in human xenograft models. This effect is mediated by increased tumor-infiltration of a rapidly proliferating progenitor-rich T cell subset.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events